focus -WSS

focus

author：fashion 2025-09-03 03:38:10 - browse：4357

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： How CO2 helps viruses stay alive longer in the air

WSS

Female surgeons have lower rates of long

ASCO Daily Recap: CAR

An outdated Medicare rule harms dementia patients with anxiety

Sutter Health’s antitrust win overturned by appeals court

Elevance PBM president out as customers face prescription chaos

Structure Therapeutics oral GLP

entertainment

focus

explore

Malaria cases in Florida and Texas: Here’s what you need to know

How doctors and nurses shape Google's AI

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Nick Jonas talks about managing diabetes along with his career

Virginia high school admissions case could be legal follow

Wellcome Trust names Røttingen as its new CEO

Peter Hotez and the public health issue of online harassment

European regulators recommend Amylyx's ALS drug be rejected

In age of alternative facts, a scholarly course on calling out crap

STAT Readout: Today's biotech news includes Sana and Amylyx

leisure time

Eli Lilly’s Zepbound improved liver scarring in mid

Wellcome Trust names Røttingen as its new CEO

There’s no way to know how good AI health technologies are

Massive project maps cells in human brain in unprecedented detail

Nick Jonas talks about managing diabetes along with his career

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

hotspot

knowledge

leisure time

leisure time